A Norwegian health panel will decide today whether to approve a new cancer treatment for multiple myeloma. The treatment, already available in Denmark and Sweden, has been previously rejected twice by the panel due to its cost. The Cancer Society expresses hope for a positive decision, highlighting the anxious wait experienced by patients and their families. The decision from the New Methods Decision Forum is keenly anticipated by those affected by the disease. Previous rejections have left patients seeking treatment options abroad or facing continued illness. The outcome will determine access to a potentially life-extending therapy within the Norwegian healthcare system.